(S)-2-[(4-Chlorophenyl)(4-piperidinyloxy)methyl]pyridine
[CAS# 201594-84-5]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyridine compound
• Name: (S)-2-[(4-Chlorophenyl)(4-piperidinyloxy)methyl]pyridine
• Synonyms: 2-[(S)-(4-chlorophenyl)-piperidin-4-yloxymethyl]pyridine
• Molecular Formula: C₁₇H₁₉ClN₂O
• Molecular Weight: 302.80
• CAS Registry Number: 201594-84-5
• SMILES: C1CNCCC1O[C@@H](C2=CC=C(C=C2)Cl)C3=CC=CC=N3

Properties

• Density: 1.21±0.1 g/cm³, Calc.^*
• Index of Refraction: 1.601, Calc.^*
• Boiling Point: 421.7±45.0 °C (760 mmHg), Calc.^*
• Flash Point: 208.8±28.7 °C, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302-H315-H319-H335
• Safety Statements: P261-P305+P351+P338

Discovery and Applications

(S)-2-[(4-Chlorophenyl)(4-piperidinyloxy)methyl]pyridine is a chemical compound that has garnered attention for its potential therapeutic applications, particularly in the field of neuroscience. This compound belongs to a class of molecules known as pyridine derivatives and exhibits distinct pharmacological properties due to its structural features. The chemical structure consists of a pyridine ring substituted with a 4-chlorophenyl group and a piperidinyloxy group, which play key roles in its biological activity.

The discovery of (S)-2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]pyridine is rooted in the search for new compounds that can modulate the activity of neurotransmitter systems, particularly those involved in cognitive function and psychiatric disorders. Research on the compound was driven by the need to develop more targeted therapies for conditions such as schizophrenia, depression, and anxiety, where neurotransmitter imbalances are often observed. By modifying the chemical structure of pyridine derivatives, scientists aimed to enhance the specificity of their interactions with neurotransmitter receptors while minimizing side effects.

(S)-2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]pyridine is believed to exert its pharmacological effects by interacting with certain receptors in the brain, including those involved in dopamine and serotonin signaling. These neurotransmitter systems are crucial for regulating mood, cognition, and behavior, making them important targets for psychiatric medications. The compound's ability to influence these systems suggests that it could have potential as a therapeutic agent for treating a variety of psychiatric conditions, including mood disorders and cognitive dysfunction.

One of the primary applications of (S)-2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]pyridine is in the development of novel treatments for schizophrenia and other neuropsychiatric disorders. Schizophrenia, in particular, is characterized by an imbalance in dopaminergic and serotoninergic signaling, and compounds that can modulate these pathways have shown promise in clinical trials. By targeting specific receptors involved in these pathways, (S)-2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]pyridine may offer a more effective and precise approach to managing symptoms of these complex disorders.

In addition to its potential use in treating psychiatric conditions, (S)-2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]pyridine may also have applications in cognitive enhancement and neuroprotection. Some studies have suggested that compounds with similar structures to (S)-2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]pyridine could help improve cognitive function in individuals with neurodegenerative diseases such as Alzheimer's disease. By promoting healthy neurotransmitter activity, such compounds could support memory, learning, and overall brain function.

The development of (S)-2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]pyridine represents a step forward in the search for more effective treatments for neuropsychiatric and cognitive disorders. Its unique chemical structure and targeted action on neurotransmitter systems offer the potential for improving patient outcomes and advancing our understanding of brain function.

While research on (S)-2-[(4-chlorophenyl)(4-piperidinyloxy)methyl]pyridine is still ongoing, the initial findings suggest that it may be a valuable addition to the arsenal of compounds used to treat a range of psychiatric and neurological conditions. Further studies are needed to fully understand its mechanisms of action, optimize its therapeutic potential, and assess its safety profile.

References

2003. Bepotastine besilate. Pharmaceutical Substances. https://pharmaceutical-substances.thieme.com/ps/search-results?docUri=KD-02-0062